Main Article Content

Qazi Syed Irfanullah Shah
Xuefeng Wan
Lv Jin
Akebaier Sulaiman
Parida Abliz


Acral Lentiginous Melanoma (ALM), Surgical outcomes, Wide local excision, Aggressive nature, Poor prognosis


Background: Acral Lentiginous Melanoma (ALM), a rare but aggressive form of cutaneous melanoma, affects about 2-3% of melanoma patients in Western populations. It primarily targets acral areas like palms, soles, and subungual regions, and is more common in individuals with darker skin tones. ALM’s unique biological and molecular properties, coupled with delayed diagnosis and lack of awareness, contribute to its aggressive nature and poorer prognosis compared to other melanoma types. Our goal was to explore the surgical management of ALM by analyzing patient demographics, tumor locations, and surgical outcomes.

Methods: We conducted a retrospective study on 50 ALM patients treated at the 1st Affiliated Hospital of Xinjiang Medical University from September 2017 to January 2022.

Results: The study's primary surgical method, wide local excision proved highly effective with no local recurrence in 50 treated cases, emphasizing its significance in managing Acral Lentiginous Melanoma (ALM). Tumor analysis revealed a predominant occurrence (66%) in acral areas, particularly the sole (36%) and heel (30%), emphasizing the need for precise surgical interventions in these locations. Demographically, ALM primarily affected individuals aged 41 to 70 (72% of cases), with a slight female preponderance (31 females, 19 males). Most cases were in the Chinese population (78%), providing comprehensive insights into the diverse patient characteristics associated with ALM. Top of Form

Conclusion: This study enhances our knowledge of ALM management by highlighting the significance of precision medicine and customized surgical strategies for improved patient outcomes. By focusing on the surgical aspects of ALM management, we aim to optimize oncological results and enhance patient well-being.

Abstract 92 | pdf Downloads 51


1. Ossio R, Roldán-Marín R, Martínez-Said H, Adams D, Robles-Espinoza CJ. Melanoma: a global perspective. Nat Rev Cancer. 2017;17(7):393-394.
2. Huang K, Fan J, Misra SJT. Acral Lentiginous Melanoma: Incidence and Survival in the United States, 2006-2015, an Analysis of the SEER Registry. J Surg Res. 2020, 251:329-339.
3. Tas F, Erturk K. Acral lentiginous melanoma is associated with certain poor prognostic histopathological factors but may not be correlated with nodal involvement, recurrence, and a worse survival. Pathobiology 2018; 85: 227–31.
4. Desai A, Ugorji R, Khachemoune A. Acral melanoma foot lesions. Part 2: clinical presentation, diagnosis, and management. Clin Exp Dermatol. 2018; 43:117–123
5. Basurto-Lozada P, Molina-Aguilar C, Castañeda-Garcia C, et al. Acral lentiginous melanoma: basic facts, biological characteristics and research perspectives of an understudied disease. Pigment Cell Melanoma Res. 2020 Apr 24. https://doi.org/10.1111/pcmr.12885.
6. Darmawan C, Jo G, Montenegro S, et al. Early detection of acral melanoma: A review of clinical. dermoscopic, histopathologic, and molecular characteristics. J Am Acad Dermatol. 2019;81(3):805-812.
7. Teramoto Y, Keim U, Gesierich A, et al. Acral lentiginous melanoma: a skin cancer with unfavorable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. Br J Dermatol. 2018, 178(2):443-451.
8. Kolla A, Vitiello G, Friedman E, et al. Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis. Cancer Control. 2021, 28:10732748211053567.
9. Nazha B, Mishra M, Pentz R, Owonikoko TK. Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy. Am Soc Clin Oncol Educ Book. 2019; 39:3–10. 10.1200/EDBK_100021
10. Cuomo R, Nisi G, Brandi C, Grimaldi L. Surgical implications of ischemia-reperfusion damage and future perspectives. J Invest Surg. 2019; 19:1-2
11. Dika E, Veronesi G, Altimari A et al. BRAF, KIT, and NRAS mutations of Acral melanoma in white patients. Am. J. Clin. Pathol. 2020; 153: 664–71.
12. Huayllani MT, Sisti A, Restrepo DJ, et al. Desmoplastic melanoma: clinical characteristics and survival in the US population. Cureus. 2019;11(6): e4931. https://doi.org/10.7759/cureus.4931
13. Huayllani MT, Bagaria SP, Restrepo DJ, et al. Wide excisional surgery in invasive melanoma treatment: factors driving non-compliance with national guidelines. Anticancer Res. 2020;40(2):1065-1069.
14. Howard M, Xie C, Wee E, et al. Acral lentiginous melanoma: clinicopathologic and survival differences according to tumor location. Australas J Dermatol. 2020 May 3. https://doi.org/10.1111/ ajd.13310.
15. Choi M, Won C, Chang S, Lee M, Lee WJ. Clinical and prognostic influence of tumor diameter in acral lentiginous melanoma. Journal of the American Academy of Dermatology. 2023, 88(2):476-479.
16. Howard M, Xie C, Wee E, et al. Acral lentiginous melanoma: Clinicopathologic and survival differences according to tumor location. Australas J Dermatol. 2020, 61(4):312-317.
17. Darmawan CC, Jo G, Montenegro SE, et al. Early detection of acral melanoma: a review of clinical, dermoscopic, histopathologic, and molecular characteristics. J Am Acad Dermatol. 2019;81(3):805-812. https://doi.org/10.1016/j.jaad.2019.01.081
18. Lee W, Lee J, Won C et al. Nail apparatus melanoma: A comparative, clinic prognostic study of the initial clinical and morphological characteristics of 49 patients. J. Am. Acad. Dermatol. 2015; 73: 213–20.
19. Pavri SN, Han G, Khan S, et al. Does sentinel lymph node status have prognostic significance in patients with acral lentiginous melanoma? J Surg Oncol. 2019; 119:1060–1069.